SPYRE THERAPEUTICS, INC. Conversion of Stock, Amount Converted
SPYRE THERAPEUTICS, INC. (SYRE) reported Conversion of Stock, Amount Converted of $9.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:ConversionOfStockAmountConverted1 · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. conversion of stock, amount converted for the quarter ending 2025-09-30 was $0.00.
- SPYRE THERAPEUTICS, INC. conversion of stock, amount converted for the quarter ending 2024-09-30 was $0.00.
- SPYRE THERAPEUTICS, INC. conversion of stock, amount converted for the quarter ending 2023-09-30 was $0.00.
| Period end | Conversion of Stock, Amount Converted 3 month | Conversion of Stock, Amount Converted 6 month | Conversion of Stock, Amount Converted 9 month |
|---|---|---|---|
| 2026-06-30 | $9.39M 10-Q · filed 2026-08-04 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-04 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $244.01M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $244.01M 10-Q · filed 2025-08-05 | ||
| 2023-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | |
| 2023-06-30 | $0.00 10-Q/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |